Ghrelin, a peptide purified from stomach, is an endogenous ligand for the growth hormone secretagogue receptor (GHS-R) and potently stimulates growth hormone (GH) release from the pituitary. Ghrelin is modified with an n-octanoyl group at Ser3. This modification is essential for the activity of ghrelin. Previously, it was not known whether other ligands for GHS-R existed.
Introduction
Growth hormone (GH) is produced and secreted from anterior pituitary gland, and exerts its actions by binding to GH receptor (1) . GH does not directly stimulate growth, but induces insulin-like growth factor-I (IGF-I) production in liver. Increased IGF-I stimulates postnatal growth. GH also directly activates several tissues to control metabolism, to regulate water and electrolyte balances, and to control cell growth and differentiation. GH is released from the pituitary gland in a pulsatile manner, regulated by episodic changes in two hypothalamic hormones, growth hormone-releasing hormone (GHRH) and somatostatin. GH secretion is stimulated by GHRH and inhibited by somatostatin (2) .
In 1976, it was revealed that modified opioid peptides had low growth hormone secretory activity (3, 4) . Since then, many efforts have been made to develop and improve potential synthetic growth hormone secretagogues (GHSs) (5) (6) (7) . GHSs are divided into two classes: peptidergic and non-peptidergic. These GHSs act on the pituitary and hypothalamus to release GH, not through the GHRH receptor but through an orphan receptor, the growth hormone secretagogue receptor (GHS-R) (8, 9) . These facts indicate that an unknown endogenous ligand for GHS-R may exist. As the endogenous ligand for GHS-R has not been identified, however, the regulatory mechanism of this growth hormone secretagogue system remains elusive. 5 succeeded in the purification of an endogenous ligand for GHS-R from stomach and named it "ghrelin" (18) . Ghrelin has a unique structure, with an n-octanoyl modification at its third serine residue essential for its activities to stimulate GH secretion from pituitary cells. The existence of ghrelin in the stomach suggests a new mechanism regulating GH secretion.
In the course of the purification of ghrelin, we noticed another active peptide that induced intracellular calcium changes in the cells expressing GHS-R. We report here the purification and characterization of this peptide. The peptide is a 27-amino acid peptide with an n-octanoyl modification at its third serine residue, identical to ghrelin except for deletion of one glutamine.
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Purification of des-Q14-ghrelin from rat stomach tissue
Des-Q14-ghrelin was purified as previously described for ghrelin (18) . Fresh rat stomach (40 g) was minced and boiled for 5 minutes in 5 x volumes of water to inactivate intrinsic proteases. The solution was adjusted to 1 M acetic acid (AcOH)-20 mM HCl. Stomach tissues were homogenized with a Polytron mixer. The supernatant of the extracts, obtained after 30-minutes centrifugation at 11,000 rpm, was concentrated to approximately 40 ml by evaporation.
A 2 x volume of acetone was added to the concentrate for acetone-precipitation in 66% acetone. HPLC on the same column at pH 4.8 to give two active peaks (P-I and P-II). The active peak was purified manually using a C-18 reverse-phase HPLC (RP-HPLC) column (Symmetry 300, 3.9 x 150 mm, Waters, Milford, MA). From the P-I, ghrelin was purified as reported previously. Des-Q14-ghrelin was purified from P-II. The primary sequence of des-Q14-ghrelin was determined using a protein sequencer (ABI 494 protein sequencer; Applied Biosystems, Foster City, CA).
Mass spectrometric analysis of des-Q14-ghrelin
Electrospary ionization mass spectrometry (ESI-MS) was performed on a quadrupole mass spectrometer SSQ7000 (Finnigan, San Jose, CA) equipped with a Finnigan ESI source. A needle capillary was heated at 150 ˚C to evaporate samples. Samples were dissolved in 50% (v/v) methanol/1% AcOH and introduced into the +4.5 kV (positive ionization) ion source at a flow rate of 5 µl/min by direct infusion with a syringe pump. Molecular masses of the purified peptides were calculated using the ICIS software Bioworks provided by Finnigan.
Peptide syntheses of des-Q14-ghrelin
Peptide syntheses of des-Q14-ghrelin were performed as previously described for ghrelin (18) . The fully protected peptide of 27-amino acids, without post-translational modifications, was Six positive phages were isolated and subcloned into plasmid pBS. Both strands of cloned cDNAs were sequenced. One of six cDNA clones encoded the prepro-des-Q14-ghrelin sequence.
Analysis of splice sites
A rat genomic library (Clontech, Palo Alto, CA) was screened using rat ghrelin cDNA as a labeled probe. Three positive phages were isolated from 4 x 10 4 phages of the library. A partial genomic fragment of rat ghrelin was obtained by PCR using a rat ghrelin genomic phage as template. Based on the rat ghrelin cDNA sequence, a primer set was designed. The sense primer, 
Southern blot analysis
Total genomic DNA (10 µg) from rat liver was digested with BamHI, EcoRI or PstI. DNA fragments were resolved by electrophoresis in 1.0% (w/v) agarose gel and transferred to a nylon membrane (Zeta-probe, BIO-RAD, Richmond, CA). For high stringency hybridization, the membrane was hybridized overnight at 42˚C in ULTRAHyb solution (Ambion, Austin, TX). For low stringency hybridization, the membrane was hybridized overnight at 37˚C in 30% formamide, 5 x SSPE, 1% SDS, 5 x Denhardt's solution and 100 µg/ml denatured salmon sperm DNA. 32 Plabeled rat ghrelin cDNA was used for hybridizations.
In vivo assay of growth hormone releasing activity
Male Wister rats (250 g) were prepared with a single indwelling jugular catheter under sodium pentobarbital. Each animal received a 1 or 5 µg injection of synthetic rat ghrelin or des-Q14-ghrelin. Blood samples were collected at 5, 10, 15, 20, 30 and 60 min after injection. All samples were centrifuged immediately and the plasmas were assayed for GH by radioimmunoassay.
Radioimmunoassay of ghrelin
A polyclonal antibody was raised against the N-terminal fragment [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 
Results
Purification of des-Q14-ghrelin
A stable CHO transfectant expressing rat GHS-R (CHO-GHSR62) was used to monitor the changes in [Ca 2+ ] i (18) . Rat stomach extracts had high activity that induced [Ca 2+ ] i increases in CHO-GHSR62 cells. Gel-filtration of stomach extracts showed that the activity was eluted at relative molecular mass (Mr) of ~3,000 (Fig. 1a) . Active fractions were further purified by CMion-exchange HPLC (Fig. 1b) . After a second CM-HPLC, active fractions were separated into two peaks (Fig. 1c) . From the main active peak (P-I), the n-octanoyl modified peptide, ghrelin, was purified as described previously (18) . Des-Q14-ghrelin was isolated from the second active peak (P-II) and further purified to homogeneity by RP-HPLC (Fig. 1d ). The yields of purified ghrelin and des-Q14-ghrelin were 16 µg and 4 µg from 40 g of rat stomach tissues, respectively.
Structural analysis of des-Q14-ghrelin
The purified peptides from P-I and P-II were subjected to protein sequencing. The amino acid sequences were determined as follow. P-I, GSXFLSPEHQKAQQRKESKKPPAKLQPR, and P-II, GSX'FLSPEHQKAQRKESKKPPAKLQPR ( Fig. 2a) , where X and X' are noctanoylated serines as described below. The P-I peak contained the rat ghrelin peptide of 28-amino acids, where X is an n-octanoyl serine. As the results of the cDNA determination and mass spectrometric analysis described below, the P-II peptide (des-Q14-ghrelin: 27 amino acids)
has the same sequence as ghrelin except missing one glutamine present in ghrelin (28 amino acids) (Fig. 2b ).
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To determine whether des-Q14-ghrelin was also modified by n-octanoyl group at the third serine, we subjected purified des-Q14-ghrelin to ESI-MS and calculated its molecular weight (Fig. 2c) . The observed molecular mass of des-Q14-ghrelin was 3187.1 ± 0.6, which is 126.7 mass units higher than the molecular mass calculated for 27-residue peptide (3060.4) (X' = Ser).
These results indicate that the hydrogen atom of the hydroxyl group in Ser3 of des-Q14-ghrelin may be replaced by a n-octanoy (C 7 H 15 CO) moiety (127 mass). This modification is the same as that of ghrelin (18) . 
Concentration of des-Q14-ghrelin
An important question is whether des-Q14-ghrelin is a mutational product of the ghrelin gene in a rat(s) or whether des-Q14-ghrelin exists in all rats. To address the question, we measured des-Q14-ghrelin concentrations in rat stomach by using a ghrelin-specific radioimmunoassay. Because the antibody used in the RIA system can recognize both ghrelin and des-Q14-ghrelin at the same level, we used CM-ion-exchange HPLC to separate des-Q14-ghrelin from ghrelin (Fig. 3) . Des-Q14-ghrelin did exist in all the rat stomachs examined. The concentration of des-Q14-ghrelin was 32 pmol/g, whereas that of ghrelin was 120 pmol/g. These 14 results indicate that ghrelin and des-Q14-ghrelin exist at considerable levels in rat stomach. 4a ). On the other hand, motilin, the endogenous ligand for a GHS-R-homologous receptor GPR38 (20), did not induced [Ca 2+ ] i increases at the peptide concentration of 10 -8 M (Fig. 4a ).
Pharmacological characterization of des-Q14-ghrelin on the GHS-R expressing cells
Des-Q14-ghrelin as well as ghrelin potently induced increases in [Ca 2+ ] i in CHO-GHSR62 cells (Fig. 4b ). EC 50 s of des-Q14-ghrelin and ghrelin are 2.4 x 10 -9 M and 2.5 x 10 -9 M, respectively.
in vivo effects of des-Q14-ghrelin on GH secretion
To confirm that des-Q14-ghrelin is a GH-releasing peptide, we intravenously injected synthetic des-Q14-ghrelin into anaesthetized rats and measured plasma GH concentrations. After injections of des-Q14-ghrelin or ghrelin, plasma GH concentrations increased with a maximum level at 10-20 min after injection (Fig. 5) . Increase in plasma GH concentration was observed from 1 µg injection of ghrelin per rat. In contrast, no increase of plasma GH concentration was observed when rats were injected with physiological saline. GH concentrations and time courses of plasma GH changes were the same when des-Q14-ghrelin or ghrelin was used. These results indicate that des-Q14-ghrelin is an endogenous GH-releasing peptide with a similar potency to ghrelin.
Southern blot analysis of rat genomic DNA
To investigate whether ghrelin homologous sequences exist, we performed a Southern blot analysis of rat liver DNA under high or low stringency hybridization conditions (21) . When rat ghrelin cDNA was used as a probe, the hybridized patterns were the same for both high and low stringency conditions (Fig. 6) . Moreover, after longer exposure times of 10 days, we could not detect extra bands. These results indicate that there is no homologous sequence to ghrelin in rat DNA.
cDNA analysis of rat prepro-des-Q14-ghrelin
Complementary DNA analysis of ghrelin mRNA from stomach revealed that there are two types of ghrelin precursors. One is the previously reported 117 amino-acid precursor (preproghrelin), which contains the 28-amino acid ghrelin (18) . The other is a 116 amino-acid precursor (prepro-des-Q14-ghrelin), which contained the des-Q14-ghrelin sequence (Fig. 7) . The nucleotide sequences of both clones are identical except for deletion of the CAG (nucletide 139-141 of prepro-ghrelin cDNA, Accession number AB029433) in the prepro-des-Q14-ghrelin cDNA at the point indicated by the triangle in figure 7 .
The ratios of the two precursor population was 1 (prepro-des-Q14-ghrelin) to 5 (preproghrelin) in the cDNA clones analyzed. This indicates that the prepro-ghrelin cDNA is preferred over the prepro-des-Q14-ghrelin cDNA in the alternative splicing in ghrelin mRNA.
Genome analysis of rat ghrelin
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To reveal whether des-Q14-ghrelin was another genomic product distinct from the ghrelin gene or whether des-Q14-ghrelin was produced through an alternative splicing of ghrelin mRNA, we determined the partial nucleic sequence of the rat ghrelin gene. The PCR amplified fragment of rat ghrelin was subcloned into a plasmid vector and sequenced. Figure 8 showed the partial genomic structure of rat ghrelin. Sequence analysis of the rat ghrelin gene revealed that an intron exists between Gln13 and Gln14 of ghrelin. Figure 8 indicates that the CAG codon of Gln13 is the end of the first exon and is followed by GT, which is the 5'-end signal of the first intron. Two AGs, boxed in figure 8, may be used as a splicing acceptor site at the 3'-end of the intron. When the second boxed AG is used as the splicing acceptor, des-Q14-ghrelin should be produced.
Alternatively, ghrelin would be produced when the first boxed AG is used as the splicing acceptor. This exon-intron boundary matches the GT-AG rule of the splicing mechanism (22).
Discussion
We report here the purification and characterization of des-Q14-ghrelin from rat stomach, a second endogenous ligand for GHS-R. Des-Q14-ghrelin is homologous to ghrelin except that one glutamine (14th Gln of ghrelin) is missing in des-Q14-ghrelin. Des-Q14-ghrelin is modified at its third serine by n-octanoyl group in a manner similar to ghrelin (18) . This n-octanoyl modification is characteristic of the structure of ghrelin. The corresponding modification of des-Q14-ghrelin is also needed to activate GHS-R. Des-Q14-ghrelin has the same potency to induce [Ca 2+ ] i increases in cells expressing GHS-R. Moreover, when des-Q14-ghrelin is injected into anesthetized rats, increases in plasma GH concentrations are observed. These results strongly indicate that des-Q14-ghrelin is another endogenous ligand for GHS-R and a novel growthhormone releasing peptide in the stomach. We also show that des-Q14-ghrelin exists in the stomachs of all rats examined and is not a mutational product of the ghrelin gene. Thus, the endogenous ligands for GHS-R are composed of two homologous peptides, ghrelin and des-Q14-ghrelin.
However, it was not clear whether ghrelin and des-Q14-ghrelin are distinct genomic products or not. Our research strongly indicates that des-Q14-ghrelin is not a distinct genomic product from the ghrelin gene, but is produced through an alternative splicing of the ghrelin gene.
First, we analyzed rat genomic DNA by Southern blot using rat ghrelin cDNA as the hybridization probe to search for ghrelin homologous sequence. Both under lower and higher stringency conditions for hybridizations, the same patterns of hybridized bands were observed.
Moreover, after longer exposure for 10 days, no additional hybridization bands were observed 18 even in low stringency conditions. These results indicate that there is no additional sequence homologous to ghrelin.
Next, we have cloned a prepro-des-Q14-ghrelin cDNA from a rat stomach cDNA library.
The nucleotide sequence of the clone is identical to that of prepro-ghrelin, except that a CAG nucleotide is missing between nucleotide 134 and 135 in prepro-des-Q14-ghrelin mRNA (Fig. 7) .
This result indicates that des-Q14-ghrelin is processed from a prepro-des-Q14-ghrelin precursor, which is the translated product of prepro-des-Q14-ghrelin mRNA.
In addition, we analyzed the genomic structure of rat ghrelin. The analysis reveals that an intron exists between Gln13 and Gln14 of the ghrelin sequence. The 3'-end of the intron has two tandem CAG sequences. The AGs of these sequences may serve as the splicing signals (22) .
When the first AG is used for the splicing signal, prepro-ghrelin mRNA is produced and the second CAG is translated into Gln14. On the other hand, when the second AG is used, preprodes-Q14-ghrelin mRNA is created to produce des-Q14-ghrelin missing Gln14.
These results confirmed that des-Q14-ghrelin is processed from the ghrelin gene by alternative splicing and is not a distinct genomic product from ghrelin. Two AGs boxed in figure   8 should serve as splice acceptor sites, producing either ghrelin or des-Q14-ghrelin mRNA accordingly.
Thus, we present here a new mechanism to produce multiple forms of a peptide hormone.
Two different ghrelin peptides, both of which are derived from a single gene, are produced through alternative splicing of the pre-mRNAs. It is well known that peptide hormones are cleaved by processing proteases to produce multiple forms of hormones (23) . Some examples are B-type natriuretic peptide (BNP) (24), C-type natriuretic peptide (CNP) (25) , prolactin releasing 
